Infectious disease
Moderna CEO Stéphane Bancel believes the promise of mRNA vaccines is so great they will become a disruptive force in preventing viral infections.
The U.S. appears to be beating back COVID-19 but it’s still raging in many parts of the world, and studies and trials are still ongoing. Here’s a look at some of today’s top COVID-19 stories.
The data may show the need for one, but vaccine and immunologists are pushing back against Pfizer and BioNTech’s contention that one is necessary now.
Approximately 100 preliminary reports of GBS have been identified out of 12.8 million doses of the J&J vaccine in the U.S., according to the Centers for Disease Control and Prevention.
HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
Last week presented a fair number of clinical trial news. Read on for more information.
The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.
Sinovac’s CoronaVac was the first COVID-19 vaccine approved in China for emergency use back in June 2020.
Ivermectin has become a contentious issue as to whether it effectively prevents and treats COVID-19. Several studies suggest it is effective, while others have indicated it is not.
PRESS RELEASES